ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 49 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $3,000 | – | 534 | +480.4% | 0.00% | – |
| Q4 2019 | $0 | -100.0% | 92 | -89.3% | 0.00% | – |
| Q3 2019 | $1,000 | -98.8% | 862 | -95.8% | 0.00% | – |
| Q2 2019 | $81,000 | -93.7% | 20,426 | -93.1% | 0.00% | -100.0% |
| Q1 2019 | $1,280,000 | +89.3% | 297,901 | +153.1% | 0.00% | – |
| Q4 2018 | $676,000 | +420.0% | 117,700 | +1130.5% | 0.00% | – |
| Q3 2018 | $130,000 | -95.7% | 9,565 | -96.2% | 0.00% | -100.0% |
| Q2 2018 | $3,025,000 | -19.8% | 254,907 | -24.1% | 0.00% | -50.0% |
| Q1 2018 | $3,771,000 | +222.9% | 335,886 | +92.0% | 0.00% | +100.0% |
| Q4 2017 | $1,168,000 | -51.0% | 174,946 | -39.9% | 0.00% | -50.0% |
| Q3 2017 | $2,383,000 | +110.5% | 291,034 | +15.4% | 0.00% | +100.0% |
| Q2 2017 | $1,132,000 | +81.1% | 252,225 | +121.8% | 0.00% | – |
| Q1 2017 | $625,000 | +281.1% | 113,706 | +387.0% | 0.00% | – |
| Q3 2016 | $164,000 | +2633.3% | 23,349 | +4569.8% | 0.00% | – |
| Q4 2015 | $6,000 | – | 500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |